Fewer injection site reactions in patients using Avonex Sep 12, 2009
Decreased peripheral blood counts in all cell lines, including rare pancytopenia and thrombocytopenia, have been reported from post-marketing experience. Severe hepatic injury, including cases of hepatic failure, has been reported rarely in patients taking AVONEX. Patients should be monitored for signs of hepatic injury and caution exercised when AVONEX is used concomitantly with other drugs associated with hepatic injury. (EurekAlert!)
A Man with Skin and Pulmonary Lesions after Bone Marrow Transplantation Jul 16, 2009
Since that time, the patient had been hospitalized repeatedly elsewhere for pancytopenia and had received transfusions of red cells and platelets. (The results of laboratory tests obtained 12 weeks before admission to this hospital are shown in Table 1. (New England Journal of Medicine)
Threshold Pharmaceuticals Presents Encouraging Data From Clinical Trials of TH-302 for Solid Tumors May 31, 2009
To date there has been one case of pancytopenia (a reduction in the number of red and white blood cells, as well as platelets) at 670 mg/m2 and one DLT of grade 3 fatigue in the initial patient dosed at 940 mg/m2. Combination Therapy Results. (Primezone Releases)
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis May 14, 2009
Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers ... g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with CIMZIA. The causal relationship of these events to CIMZIA remains unclear. (PR Newswire)
IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte(R) (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients Feb 14, 2009
Valcyte tablets should not be administered if the absolute neutrophil count is less than 500 cells/micro liter, the platelet count is less than 25,000/micro liter, or the hemoglobin is less than 8 g/dL. Severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone morrow depression, and aplastic anemia have been observed in patients treated with Valcyte tablets (and ganciclovir). Other adverse events reported with frequency of greater or equal to 5% included diarrhea, tremors,... (PR Newswire)
